ATE222493T1 - Induktion der zelldifferenzierung mit mevalonat und mevalonolaktonderivaten - Google Patents

Induktion der zelldifferenzierung mit mevalonat und mevalonolaktonderivaten

Info

Publication number
ATE222493T1
ATE222493T1 AT92912191T AT92912191T ATE222493T1 AT E222493 T1 ATE222493 T1 AT E222493T1 AT 92912191 T AT92912191 T AT 92912191T AT 92912191 T AT92912191 T AT 92912191T AT E222493 T1 ATE222493 T1 AT E222493T1
Authority
AT
Austria
Prior art keywords
mevalonate
induction
mevalonolactone derivatives
cell differentiation
cellular function
Prior art date
Application number
AT92912191T
Other languages
English (en)
Inventor
Terence J Scallen
Paul L Mann
Original Assignee
Univ New Mexico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New Mexico filed Critical Univ New Mexico
Application granted granted Critical
Publication of ATE222493T1 publication Critical patent/ATE222493T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
AT92912191T 1991-05-01 1992-05-01 Induktion der zelldifferenzierung mit mevalonat und mevalonolaktonderivaten ATE222493T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69428491A 1991-05-01 1991-05-01
US78621591A 1991-10-31 1991-10-31
PCT/US1992/003678 WO1992019105A1 (en) 1991-05-01 1992-05-01 Cell differentiation induction with mevalonate and mevalonolactone derivatives

Publications (1)

Publication Number Publication Date
ATE222493T1 true ATE222493T1 (de) 2002-09-15

Family

ID=27105343

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92912191T ATE222493T1 (de) 1991-05-01 1992-05-01 Induktion der zelldifferenzierung mit mevalonat und mevalonolaktonderivaten

Country Status (7)

Country Link
US (2) US5783594A (de)
EP (2) EP1188439A3 (de)
JP (1) JPH07500313A (de)
AT (1) ATE222493T1 (de)
CA (1) CA2109120A1 (de)
DE (1) DE69232743T2 (de)
WO (1) WO1992019105A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500313A (ja) * 1991-05-01 1995-01-12 ユニバーシティ、オブ、ニューメキシコ メバロナート及びメバロノラクトン誘導体による細胞分化誘導
EP1322306A2 (de) * 2000-09-19 2003-07-02 NovImmune S.A. Verwendung von statine (hmg-coa reduktase inhibitoren) zur herstellung eines medikamentes als neue arten von immunomodulatorischen, immunosuppressorischen und antiinflammatorischen mitteln
US6902881B2 (en) * 2000-10-13 2005-06-07 President And Fellows Of Harvard College Compounds and methods for regulating cell differentiation
US8729092B2 (en) 2012-09-24 2014-05-20 Terence J. Scallen Rosuvastatin enantiomer compounds
WO2021218988A1 (zh) * 2020-04-30 2021-11-04 中国科学院上海药物研究所 Prdx1激动剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4808607A (en) * 1985-05-22 1989-02-28 Sandoz Pharm. Corp. Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level
US4755606A (en) * 1985-05-22 1988-07-05 Sandoz Pharm. Corp. Imidazolyl-3,5-di-(diphenyl-butylsilyloxy) carboxylic acid ester intermediates
US4933185A (en) * 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US4933165A (en) * 1989-01-18 1990-06-12 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5001148A (en) * 1989-06-07 1991-03-19 E. R. Squibb & Sons, Inc. Mevinic acid derivatives
US4970221A (en) * 1989-07-28 1990-11-13 E. R. Squibb & Sons, Inc. 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5173487A (en) * 1989-11-13 1992-12-22 E. R. Squibb & Sons, Inc. Mevinic acid derivatives
CA2052014A1 (en) * 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
JPH07500313A (ja) * 1991-05-01 1995-01-12 ユニバーシティ、オブ、ニューメキシコ メバロナート及びメバロノラクトン誘導体による細胞分化誘導

Also Published As

Publication number Publication date
US5849777A (en) 1998-12-15
EP1188439A2 (de) 2002-03-20
US5783594A (en) 1998-07-21
CA2109120A1 (en) 1992-11-12
JPH07500313A (ja) 1995-01-12
DE69232743D1 (de) 2002-09-26
EP0675715A4 (de) 1995-06-12
EP1188439A3 (de) 2003-10-22
WO1992019105A1 (en) 1992-11-12
DE69232743T2 (de) 2003-05-28
EP0675715B1 (de) 2002-08-21
EP0675715A1 (de) 1995-10-11

Similar Documents

Publication Publication Date Title
PT699192E (pt) Compostos oxazolilo substituidos para o tratamento de inflamacao
IT9047580A0 (it) Procedimento di trattamento di polveri inorganiche.
ATE239477T1 (de) Chinolone und deren therapeutische verwendung
AU5218993A (en) Novel sulphonamides
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
NL300140I1 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
NO903640D0 (no) Fremgangsmaate for fremstilling av 2-(rs)-substituerte 2,3-dihydro-5-oksy-4,6,7-trimetylbenzofuraner.
NO161972C (no) Analogifremgamgsmaate ved fremstilling av terapeutisk aktive 1-substituerte tetralinderivater.
ATE222493T1 (de) Induktion der zelldifferenzierung mit mevalonat und mevalonolaktonderivaten
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
ITTO930178A0 (it) Pressa per la costruzione di cingoli
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
NO913117L (no) Fremgangsmaate for behandling av benoedeleggende sykdommer.
FR2658419B1 (fr) Medicament pour le traitement de la dermatite.
KR950700738A (ko) 당뇨병 치료를 위한 퀴놀린-3-카르복시아미드 화합물의 용도(the use of quinoline-3-carboxamide compounds for treatment of diabetes)
CY1106882T1 (el) Τροποποιηση βητακυτταρουλινης
DE59310127D1 (de) Benzothiazolderivate als Vulkanisationsbeschleuniger, die sich zur Einführung von polaren Substituenten eignen
AU7593091A (en) Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
AU558439B2 (en) Polyackyldiazaspirodecane derivatives
TR199701605A2 (xx) S�lfonamid-substit�e edilmi� bile�ikler
ATE127806T1 (de) Antibiotikverbindungen und ihre herstellung.
DE69015411D1 (de) 5,11-Dihydro-6H-pyrido(2,3-b)(1,4)benzodiazepin-6-one und -thione und deren Verwendung bei der Vorbeugung und und Behandlung von AIDS.
SU959235A1 (ru) Стабилизированный преобразователь посто нного напр жени
FR2581601B1 (fr) Perfectionnement apporte aux unites de pesages mobiles pour experimentations agricoles
ATE158293T1 (de) Polycyclische 31668p- und 31668u-verbindungen, verfahren zu ihrer herstellung und ihre verwendung als antibiotische oder antitumorale arzneistoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties